An IHC-derived TLS–CD8–macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC - Top-Institutions - MDSpire

An IHC-derived TLS–CD8–macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC

  • By

  • Jingyu Tan

  • Yan Liu

  • Binbin Wang

  • Haiwen Liu

  • June 19, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    CheckMate 816
    CheckMate 816

    N/A, N/A

    Key Differentiators

    • Oncology

  • #2

    The University of Hong Kong
    The University of Hong Kong

    Hong Kong, N/A

    Key Differentiators

    • Oncology

  • #3

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Oncology

  • #5

    Gustave Roussy
    Gustave Roussy

    Villejuif, N/A

    Key Differentiators

    • Oncology

Original Source(s)

An IHC-derived TLS–CD8–macrophage immune niche score predicts major pathological response to neoadjuvant chemoimmunotherapy in resectable NSCLC

  • by Jingyu Tan, Yan Liu, Binbin Wang, Haiwen Liu

  • June 19, 2026

Related Content

HuBIE: The human blood immunome encyclopedia of TCRs and BCRs in bloodstream infections and cancer

Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report

Hepatic metastasis of mucinous adenocarcinoma with neuroendocrine differentiation harboring a rare HER2 R678Q mutation: a case report and literature review